200,000+ products from a single source!
sales@angenechem.com
251565-85-2 | Benzenepropanoic acid, α-ethoxy-4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]-, (αS)-
CAS No: 251565-85-2 Catalog No: AG002QO8 MDL No:MFCD07784004
Product Description
Catalog Number:
AG002QO8
Chemical Name:
Benzenepropanoic acid, α-ethoxy-4-[2-[4-[(methylsulfonyl)oxy]phenyl]ethoxy]-, (αS)-
CAS Number:
251565-85-2
Molecular Formula:
C20H24O7S
Molecular Weight:
408.4654
MDL Number:
MFCD07784004
IUPAC Name:
(2S)-2-ethoxy-3-[4-[2-(4-methylsulfonyloxyphenyl)ethoxy]phenyl]propanoic acid
InChI:
InChI=1S/C20H24O7S/c1-3-25-19(20(21)22)14-16-6-8-17(9-7-16)26-13-12-15-4-10-18(11-5-15)27-28(2,23)24/h4-11,19H,3,12-14H2,1-2H3,(H,21,22)/t19-/m0/s1
InChI Key:
CXGTZJYQWSUFET-IBGZPJMESA-N
SMILES:
CCO[C@H](C(=O)O)Cc1ccc(cc1)OCCc1ccc(cc1)OS(=O)(=O)C
UNII:
6734037O3L
Properties
Complexity:
556
Compound Is Canonicalized:
Yes
Covalently-Bonded Unit Count:
1
Defined Atom Stereocenter Count:
1
Defined Bond Stereocenter Count:
0
Exact Mass:
408.124g/mol
Formal Charge:
0
Heavy Atom Count:
28
Hydrogen Bond Acceptor Count:
7
Hydrogen Bond Donor Count:
1
Isotope Atom Count:
0
Molecular Weight:
408.465g/mol
Monoisotopic Mass:
408.124g/mol
Rotatable Bond Count:
11
Topological Polar Surface Area:
108A^2
Undefined Atom Stereocenter Count:
0
Undefined Bond Stereocenter Count:
0
XLogP3:
3.5
Literature
| Title | Journal |
|---|---|
| PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells. | Toxicology and applied pharmacology 20140401 |
| Design, synthesis and evaluation of novel zwitterionic compounds as PPARα/γ dual agonists (1). | Bioorganic & medicinal chemistry letters 20121201 |
| PPAR agonists for the treatment of cardiovascular disease in patients with diabetes. | Diabetes, obesity & metabolism 20121101 |
| Pharmacokinetic-pharmacodynamic assessment of the interrelationships between tesaglitazar exposure and renal function in patients with type 2 diabetes mellitus. | Journal of clinical pharmacology 20120901 |
| The cardiovascular effects of peroxisome proliferator-activated receptor agonists. | The American journal of medicine 20120201 |
| Tesaglitazar, a dual PPAR-α/γ agonist, hamster carcinogenicity, investigative animal and clinical studies. | Toxicologic pathology 20120101 |
| Lipidomics reveals multiple pathway effects of a multi-components preparation on lipid biochemistry in ApoE*3Leiden.CETP mice. | PloS one 20120101 |
| Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes. | PloS one 20120101 |
| Efficacy of various antidiabetic agents as add-on treatments to metformin in type 2 diabetes mellitus: systematic review and meta-analysis. | ISRN endocrinology 20120101 |
| A fast method for testing covariates in population PK/PD Models. | The AAPS journal 20110901 |
| Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in rat hepatocytes. | Toxicology and applied pharmacology 20110701 |
| Revisiting glitazars: thiophene substituted oxazole containing α-ethoxy phenylpropanoic acid derivatives as highly potent PPARα/γ dual agonists devoid of adverse effects in rodents. | Bioorganic & medicinal chemistry letters 20110515 |
| Proliferative and molecular effects of the dual PPARalpha/gamma agonist tesaglitazar in rat adipose tissues: relevance for induction of fibrosarcoma. | Toxicologic pathology 20110201 |
| Effect of structurally constrained oxime-ether linker on PPAR subtype selectivity: Discovery of a novel and potent series of PPAR-pan agonists. | Bioorganic & medicinal chemistry 20110115 |
| Animal models of cardiovascular diseases. | Journal of biomedicine & biotechnology 20110101 |
| Comparative gene expression profiles induced by PPARγ and PPARα/γ agonists in human hepatocytes. | PloS one 20110101 |
| Pleiotropic effects of glitazones: a double edge sword? | Frontiers in pharmacology 20110101 |
| Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators. | The open medicinal chemistry journal 20110101 |
| Successful drug development despite adverse preclinical findings part 2: examples. | Journal of toxicologic pathology 20101201 |
| A model for glucose, insulin, and beta-cell dynamics in subjects with insulin resistance and patients with type 2 diabetes. | Journal of clinical pharmacology 20100801 |
| Tesaglitazar, a dual peroxisome proliferator-activated receptor agonist (PPAR alpha/gamma), improves metabolic abnormalities and reduces renal injury in obese Zucker rats. | Nephron. Experimental nephrology 20100101 |
| Peroxisome proliferator-activated receptor alpha and alpha/gamma agonists do not cause impairment in renal function in the rat. | Nephron. Physiology 20100101 |
| Gene Expression Changes Induced by PPAR Gamma Agonists in Animal and Human Liver. | PPAR research 20100101 |
| PPAR-alpha and PPAR-gamma agonists for type 2 diabetes. | Lancet (London, England) 20090711 |
| 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part. II: Synthesis and pharmacological evaluation of oxime and acidic head group structural variations. | Bioorganic & medicinal chemistry letters 20090515 |
| The dual PPARalpha/gamma agonist tesaglitazar blocks progression of pre-existing atherosclerosis in APOE*3Leiden.CETP transgenic mice. | British journal of pharmacology 20090401 |
| A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease. | Cardiovascular diabetology 20090101 |
| Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists. | Journal of medicinal chemistry 20081023 |
| Discovery of a highly orally bioavailable c-5-[6-(4-Methanesulfonyloxyphenyl)hexyl]-2-methyl-1,3-dioxane-r-2-carboxylic acid as a potent hypoglycemic and hypolipidemic agent. | Bioorganic & medicinal chemistry letters 20081015 |
| Design, synthesis, and evaluation of novel aryl-tetrahydropyridine PPARalpha/gamma dual agonists. | Bioorganic & medicinal chemistry letters 20080915 |
| Models for plasma glucose, HbA1c, and hemoglobin interrelationships in patients with type 2 diabetes following tesaglitazar treatment. | Clinical pharmacology and therapeutics 20080801 |
| Design and synthesis of novel oxazole containing 1,3-dioxane-2-carboxylic acid derivatives as PPAR alpha/gamma dual agonists. | Bioorganic & medicinal chemistry 20080801 |
| Mechanistic modelling of tesaglitazar pharmacokinetic data in subjects with various degrees of renal function--evidence of interconversion. | British journal of clinical pharmacology 20080601 |
| Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, improves apolipoprotein levels in non-diabetic subjects with insulin resistance. | Atherosclerosis 20080301 |
| Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents. | Bioorganic & medicinal chemistry 20080301 |
| 4,4-Dimethyl-1,2,3,4-tetrahydroquinoline-based PPARalpha/gamma agonists. Part I: synthesis and pharmacological evaluation. | Bioorganic & medicinal chemistry letters 20080301 |
| PPAR Agonists and Cardiovascular Disease in Diabetes. | PPAR research 20080101 |
| Should We Use PPAR Agonists to Reduce Cardiovascular Risk? | PPAR research 20080101 |
| Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders. | PPAR research 20080101 |
| PPARgamma and Agonists against Cancer: Rational Design of Complementation Treatments. | PPAR research 20080101 |
| Mild electrical stimulation with heat shock ameliorates insulin resistance via enhanced insulin signaling. | PloS one 20080101 |
| Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists. | PPAR research 20080101 |
| PPARgamma in Kidney Physiology and Pathophysiology. | PPAR research 20080101 |
| Tesaglitazar, a dual peroxisome proliferator-activated receptor alpha/gamma agonist, reduces atherosclerosis in female low density lipoprotein receptor deficient mice. | Atherosclerosis 20071101 |
| The dual peroxisome proliferator-activated receptor alpha/gamma agonist tesaglitazar further improves the lipid profile in dyslipidemic subjects treated with atorvastatin. | Metabolism: clinical and experimental 20070901 |
| Learning from tesaglitazar. | Diabetes & vascular disease research 20070901 |
| Improvement of postprandial lipid handling and glucose tolerance in a non-diabetic population by the dual PPARalpha/gamma agonist, tesaglitazar. | Diabetes & vascular disease research 20070901 |
| A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus. | Diabetes & vascular disease research 20070901 |
| Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. | Diabetes & vascular disease research 20070901 |
| The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes. | Diabetes & vascular disease research 20070901 |
| Efficacy, safety and tolerability of tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes. | Diabetes & vascular disease research 20070901 |
| PPAR dual agonists: are they opening Pandora's Box? | Pharmacological research 20070801 |
| Peroxisome proliferator activated receptor alpha/gamma dual agonist tesaglitazar attenuates diabetic nephropathy in db/db mice. | Diabetes 20070801 |
| Tesaglitazar, a PPARalpha/gamma agonist, induces interstitial mesenchymal cell DNA synthesis and fibrosarcomas in subcutaneous tissues in rats. | Toxicological sciences : an official journal of the Society of Toxicology 20070701 |
| Quinoline-based derivatives of pirinixic acid as dual PPAR alpha/gamma agonists. | Archiv der Pharmazie 20070701 |
| Design and synthesis of oxime ethers of alpha-acyl-beta-phenylpropanoic acids as PPAR dual agonists. | Bioorganic & medicinal chemistry letters 20070215 |
| PPARalpha and PPARgamma dual agonists for the treatment of type 2 diabetes and the metabolic syndrome. | Current opinion in pharmacology 20061201 |
| Effect of tesaglitazar, a dual PPAR alpha/gamma agonist, on glucose and lipid abnormalities in patients with type 2 diabetes: a 12-week dose-ranging trial. | Current medical research and opinion 20061201 |
| Dual PPARalpha/gamma agonist tesaglitazar reduces atherosclerosis in insulin-resistant and hypercholesterolemic ApoE*3Leiden mice. | Arteriosclerosis, thrombosis, and vascular biology 20061101 |
| Food does not affect the pharmacokinetics of tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist. | Journal of clinical pharmacology 20060901 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20060501 |
| Diabetes: assessing the pipeline. | Atherosclerosis. Supplements 20060401 |
| Tesaglitazar: a promising approach in type 2 diabetes. | Drugs of today (Barcelona, Spain : 1998) 20060301 |
| Therapeutic options in development for management of diabetes: pharmacologic agents and new technologies. | Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20060101 |
| Tesaglitazar. | IDrugs : the investigational drugs journal 20051101 |
| Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats. | American journal of physiology. Regulatory, integrative and comparative physiology 20051001 |
| Tesaglitazar, a novel dual peroxisome proliferator-activated receptor alpha/gamma agonist, dose-dependently improves the metabolic abnormalities associated with insulin resistance in a non-diabetic population. | Diabetologia 20050901 |
| American Diabetes Association - 65th Scientific Sessions. PPAR agents. | IDrugs : the investigational drugs journal 20050801 |
| Exploring the binding site structure of the PPAR gamma ligand-binding domain by computational solvent mapping. | Biochemistry 20050201 |
| Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons. | Cardiovascular diabetology 20050101 |
| Peroxisome proliferator-activated receptor-gamma and its agonists in hypertension and atherosclerosis : mechanisms and clinical implications. | American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101 |
| Pharmacokinetics and metabolism of tesaglitazar, a novel dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist, after a single oral and intravenous dose in humans. | Drug metabolism and disposition: the biological fate of chemicals 20040901 |
| Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes. | Journal of medicinal chemistry 20040812 |
| Peroxisome proliferator-activated receptor (PPAR) activation induces tissue-specific effects on fatty acid uptake and metabolism in vivo--a study using the novel PPARalpha/gamma agonist tesaglitazar. | Endocrinology 20040701 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20031101 |
| Gateways to clinical trials. | Methods and findings in experimental and clinical pharmacology 20031001 |
| Factorial design for the development of automated solid-phase extraction in the 96-well format for determination of tesaglitazar, in plasma, by liquid chromatography-mass spectrometry. | Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20030425 |
| Synthesis and biological and structural characterization of the dual-acting peroxisome proliferator-activated receptor alpha/gamma agonist ragaglitazar. | Journal of medicinal chemistry 20030410 |
| AZ 242, a novel PPARalpha/gamma agonist with beneficial effects on insulin resistance and carbohydrate and lipid metabolism in ob/ob mice and obese Zucker rats. | Journal of lipid research 20021101 |
| Tesaglitazar AstraZeneca. | IDrugs : the investigational drugs journal 20020901 |
| Structure of the PPARalpha and -gamma ligand binding domain in complex with AZ 242; ligand selectivity and agonist activation in the PPAR family. | Structure (London, England : 1993) 20010801 |
Related Products
Featured Products
© 2019 Angene International Limited. All rights Reserved.